EGF and neoplasm: In vitro, targets EGFR‐positive cancer cells (MDA‐MB‐468). In vivo, intravenous injection to MDA‐MB‐468 xenografted mice. 2.8% ID g−1 in the tumor after 72 h. Tumor uptake enhanced by coadministration of free EGF blocking hepatic EGFR.